Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 692
Filter
1.
PLoS One ; 17(2): e0264275, 2022.
Article in English | MEDLINE | ID: mdl-35213623

ABSTRACT

BACKGROUND: Serum fructosamine is a routine test used for clinical monitoring of diabetes mellitus (DM) but the usefulness of HbA1c for this purpose has not been extensively studied. HYPOTHESIS: The study aimed to compare the ability of blood HbA1c and serum fructosamine tests to correctly classify DM control determined using a clinically-based assessment. ANIMALS: 28 client-owned dogs with naturally-occurring diabetes mellitus. METHODS: Cross-sectional observational study. Ability of fructosamine and HbA1c tests to classify diabetes control in dogs was determined. RESULTS: Clinical assessment classified 50% of dogs as having good diabetic control and 82% as having acceptable diabetic control. Analysis using Cohen's kappa test showed that agreements between fructosamine and HbA1c results and the clinical assessment ranged from poor to fair. Fructosamine and HbA1c results from each dog showed a moderate correlation. Overall, the HbA1c test showed the best agreement with the clinical assessment when diabetes control was considered either acceptable or unacceptable, although the strength of agreement was considered fair (kappa = 0.27). CONCLUSIONS AND CLINICAL IMPORTANCE: The HbA1c concentration was found to be more consistent with clinical evaluation of diabetes control than was the serum fructosamine concentration. The HbA1c level is a useful tool for assessment of glycemic status in diabetic dogs but should be used alongside other tests for outpatient monitoring of clinically stable diabetic dogs.


Subject(s)
Diabetes Mellitus/blood , Diabetes Mellitus/veterinary , Dog Diseases/blood , Fructosamine/blood , Glycated Hemoglobin/metabolism , Animals , Dogs , Female , Glycemic Control , Male
2.
Can J Vet Res ; 86(1): 52-58, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34975223

ABSTRACT

The aim of this study was to investigate the effect of bexagliflozin on glycemic control in poorly regulated diabetic cats and to evaluate for adverse events associated with this medication. Sodium-glucose cotransporter 2 inhibitors are a newer class of drugs used in the management of humans with type 2 diabetes mellitus. The objective of this study was to evaluate the effect of the orally administered drug, bexagliflozin in a group of poorly regulated diabetic cats over a 4-week study period. Five client-owned cats with poorly controlled diabetes mellitus receiving insulin therapy were enrolled. Bexagliflozin was administered once daily. Serum fructosamine, serum biochemistry profile, and 10-hour blood glucose curves were assessed at baseline (Day 0), Day 14, and Day 28. All cats had a significant reduction in insulin dose requirement (P = 0.015) and insulin was discontinued in 2 cats. There was a significant decrease in blood glucose concentration obtained from blood glucose concentration curves during the study period (P = 0.022). Serum fructosamine decreased in 4 of the 5 cats with a median decrease of 152 µmol/L (range: 103 to 241 µmol/L), which was not statistically significant (P = 0.117). No cats had any documented episodes of hypoglycemia. Adverse effects were mild. The addition of bexagliflozin significantly improved diabetic management in this group of cats.


Le but de cette étude était d'étudier l'effet de la bexagliflozine sur la maitrise de la glycémie chez les chats diabétiques mal régulés et d'évaluer les événements indésirables associés à ce médicament. Les inhibiteurs du cotransporteur sodium-glucose 2 sont une nouvelle classe de médicaments utilisés dans la prise en charge des personnes atteintes de diabète de type 2. L'objectif de cette étude était d'évaluer l'effet du médicament administré par voie orale, la bexagliflozine, dans un groupe de chats diabétiques mal régulés sur une période d'étude de 4 semaines. Cinq chats appartenant à des clients atteints de diabète sucré mal maitrisé et recevant une insulinothérapie ont été inclus. La bexagliflozine a été administrée une fois par jour. La fructosamine sérique, le profil biochimique sérique et les courbes de glycémie sur 10 heures ont été évalués au départ (jour 0), au jour 14 et au jour 28. Tous les chats ont présenté une réduction significative de la dose d'insuline requise (P = 0,015) et l'insuline a été interrompue chez deux chats. Il y avait une diminution significative de la concentration de glucose dans le sang obtenue à partir des courbes de concentration de glucose dans le sang au cours de la période d'étude (P = 0,022). La fructosamine sérique a diminué chez 4 des 5 chats avec une diminution médiane de 152 µmol/L (plage : 103 à 241 µmol/L), ce qui n'était pas statistiquement significatif (P = 0,117). Aucun chat n'a eu d'épisodes documentés d'hypoglycémie. Les effets indésirables étaient légers. L'ajout de bexagliflozine a considérablement amélioré la gestion du diabète dans ce groupe de chats.(Traduit par Docteur Serge Messier).


Subject(s)
Cat Diseases , Diabetes Mellitus, Type 2 , Pyrans , Administration, Oral , Animals , Blood Glucose/drug effects , Cat Diseases/blood , Cat Diseases/drug therapy , Cats , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/veterinary , Fructosamine/blood , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/pharmacology , Insulin/therapeutic use , Pyrans/administration & dosage , Pyrans/adverse effects , Pyrans/pharmacology , Treatment Outcome
3.
BJOG ; 129(4): 619-626, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34529344

ABSTRACT

OBJECTIVE: To evaluate the association between maternal fructosamine levels at the time of delivery and stillbirth. DESIGN: Secondary analysis of a case-control study. SETTING: Multicentre study of five geographic catchment areas in the USA. POPULATION: All singleton stillbirths with known diabetes status and fructosamine measurement, and representative live birth controls. MAIN OUTCOME MEASURES: Fructosamine levels in stillbirths and live births among groups were adjusted for potential confounding factors, including diabetes. Optimal thresholds of fructosamine to discriminate stillbirth and live birth. RESULTS: A total of 529 women with a stillbirth and 1499 women with a live birth were included in the analysis. Mean fructosamine levels were significantly higher in women with a stillbirth than in women with a live birth after adjustment (177 ± 3.05 versus 165 ± 2.89 µmol/L, P < 0.001). The difference in fructosamine levels between stillbirths and live births was greater among women with diabetes (194 ± 8.54 versus 162 ± 3.21 µmol/L), compared with women without diabetes (171 ± 2.50 versus 162 ± 2.56 µmol/L). The area under the curve (AUC) for fructosamine level and stillbirth was 0.634 (0.605-0.663) overall, 0.713 (0.624-0.802) with diabetes and 0.625 (0.595-0.656) with no diabetes. CONCLUSIONS: Maternal fructosamine levels at the time of delivery were higher in women with stillbirth compared with women with live birth. Differences were substantial in women with diabetes, suggesting a potential benefit of glycaemic control in women with diabetes during pregnancy. The small differences noted in women without diabetes are not likely to justify routine screening in all cases of stillbirth. TWEETABLE ABSTRACT: Maternal serum fructosamine levels are higher in women with stillbirth than in women with live birth, especially in women with diabetes.


Subject(s)
Fructosamine/blood , Stillbirth/epidemiology , Adult , Case-Control Studies , Causality , Female , Humans , Live Birth/epidemiology , Pregnancy , ROC Curve , Risk Factors , United States/epidemiology
4.
Diabetes ; 71(2): 359-364, 2022 02 01.
Article in English | MEDLINE | ID: mdl-34753797

ABSTRACT

Fructosamine is a measure of short-term glycemic control, which has been suggested as a useful complement to glycated hemoglobin (HbA1c) for the diagnosis and monitoring of diabetes. To date, a single genome-wide association study (GWAS) including 8,951 U.S. White and 2,712 U.S. Black individuals without a diabetes diagnosis has been published. Results in Whites and Blacks yielded different association loci, near RCN3 and CNTN5, respectively. In this study, we performed a GWAS on 20,731 European-ancestry blood donors and meta-analyzed our results with previous data from U.S. White participants from the Atherosclerosis Risk in Communities (ARIC) study (Nmeta = 29,685). We identified a novel association near GCK (rs3757840, ßmeta = 0.0062; minor allele frequency [MAF] = 0.49; Pmeta = 3.66 × 10-8) and confirmed the association near RCN3 (rs113886122, ßmeta = 0.0134; MAF = 0.17; Pmeta = 5.71 × 10-18). Colocalization analysis with whole-blood expression quantitative trait loci data suggested FCGRT as the effector transcript at the RCN3 locus. We further showed that fructosamine has low heritability (h2 = 7.7%), has no significant genetic correlation with HbA1c and other glycemic traits in individuals without a diabetes diagnosis (P > 0.05), but has evidence of shared genetic etiology with some anthropometric traits (Bonferroni-corrected P < 0.0012). Our results broaden knowledge of the genetic architecture of fructosamine and prioritize FCGRT for downstream functional studies at the established RCN3 locus.


Subject(s)
Calcium-Binding Proteins/genetics , Fructosamine/blood , Histocompatibility Antigens Class I/genetics , Receptors, Fc/genetics , Adult , Atherosclerosis/blood , Atherosclerosis/epidemiology , Atherosclerosis/genetics , Cohort Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/genetics , Female , Fructosamine/metabolism , Gene Expression Regulation , Gene Frequency , Genetic Loci , Genetic Variation , Genome-Wide Association Study , Glycated Hemoglobin/metabolism , Humans , Male , Metabolic Networks and Pathways/genetics , Polymorphism, Single Nucleotide , United Kingdom/epidemiology , United States/epidemiology
5.
Int J Mol Sci ; 22(10)2021 May 15.
Article in English | MEDLINE | ID: mdl-34063487

ABSTRACT

Conflicting reports exist with regard to the effect of ecdysterone, the predominating representative of steroid hormones in insects and plants, on hepatic and plasma lipid concentrations in different rodent models of obesity, fatty liver, and diabetes, indicating that the effect is dependent on the rodent model used. Here, the hypothesis was tested for the first time that ecdysterone causes lipid-lowering effects in genetically obese Zucker rats. To test this hypothesis, two groups of male obese Zucker rats (n = 8) were fed a nutrient-adequate diet supplemented without or with 0.5 g ecdysterone per kg diet. To study further if ecdysterone is capable of alleviating the strong lipid-synthetic activity in the liver of obese Zucker rats, the study included also two groups of male lean Zucker rats (n = 8) which also received either the ecdysterone-supplemented or the non-supplemented diet. While hepatic and plasma concentrations of triglycerides and cholesterol were markedly higher in the obese compared to the lean rats (p < 0.05), hepatic and plasma triglyceride and cholesterol concentrations did not differ between rats of the same genotype fed the diets without or with ecdysterone. In conclusion, the present study clearly shows that ecdysterone supplementation does not exhibit lipid-lowering actions in the liver and plasma of lean and obese Zucker rats.


Subject(s)
Ecdysterone/metabolism , Ecdysterone/pharmacology , Lipid Metabolism/physiology , Liver/drug effects , Obesity/metabolism , Animals , Dietary Supplements , Fructosamine/blood , Gene Expression Profiling , Gene Expression Regulation/drug effects , Genotype , Lipid Metabolism/drug effects , Lipids/blood , Liver/metabolism , Male , Organ Size/drug effects , Rats, Zucker , Reproducibility of Results
6.
Med Arch ; 75(1): 11-15, 2021 Feb.
Article in English | MEDLINE | ID: mdl-34012192

ABSTRACT

BACKGROUND: Disorders of thyroid gland are common in general population, and it's the most common affecting the endocrine system after diabetes mellitus. Thyroid function regulates a wide range of metabolic parameters, as well as affects some cardiovascular disease risk factors. Fructosamine is produced by a reaction between albumin (protein) and glucose; it is used to monitor patients with diabetes for short-term glycemic changes. H-FABP is present in the cytoplasm of cardiac myocytes, and delivers fatty acids into these cells. It has been shown to increase in myocardial injury. Lipoprotein LP(a) is consist of a special apolipoprotein called apoprotein (a), and it's recognized as a cardiovascular disease independent risk factor. OBJECTIVE: To study whether certain metabolic and cardiovascular markers (fructosamine, H-FABP and lipoprotein (a) are changed in hypothyroid patients. METHODS: The current study included 280 overt hypothyroid, 272 with subclinical hypothyroidism compared with 270 healthy individuals of matched age and gender. For all subjects serum (TSH, T4, T3, FBS, HbA1c, fructosamine, triglycerides, cholesterol, lipoprotein (a), and Heart-type Fatty Acid-Binding Protein (H-FABP)) was measured. RESULTS: Serum fructosamine level significantly elevated (p value <0.05) in patient with hypothyroidism when compared with control group, and no significant change between subclinical and control groups. There is no significant change in serum H-FABP between study subjects. There is significant increase in lipoprotein (a) in patient with hypothyroidism and those with subclinical group when compared with control group. CONCLUSION: Serum fructosamine and level is significantly changed in patients with overt hypothyroidism when compared with euthyroid subjects. Also, we conclude that hypothyroidism increase risk of cardiovascular diseases by changing non-traditional marker such as lipoprotein (a), and no effect on H-FABP concentration.


Subject(s)
Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Hypothyroidism/blood , Hypothyroidism/diagnosis , Metabolic Diseases/blood , Metabolic Diseases/diagnosis , Adult , Fatty Acid Binding Protein 3/blood , Female , Fructosamine/blood , Healthy Volunteers , Humans , Hypothyroidism/physiopathology , Iraq , Lipoprotein(a)/blood , Male , Middle Aged
7.
J Pharm Pharmacol ; 73(10): 1361-1368, 2021 Sep 07.
Article in English | MEDLINE | ID: mdl-33772554

ABSTRACT

OBJECTIVES: This study was carried out to evaluate the effects of flavonoids present in leaves of Passiflora edulis fruit on complications induced by diabetes in rats. METHODS: The extract of P. edulis leaf was obtained by 70% ethanol maceration. From the dry extract, the fractions were obtained by consecutive liquid-liquid partition with hexane, ethyl acetate and n-butanol. The content of isoorientin of ethyl acetate and n-butanol fractions was determined by ultra-performance liquid chromatography coupled with electrospray and triple quadrupole ionization (TQD) analysis in tandem mass spectrometry (UPLC-ESI-Tq-MS). Only Fr-BuOH was used to treat diabetic or not Wistar rats. Biochemical parameters, platelet aggregation and production of reactive species were evaluated. KEY FINDINGS: The UPLC-ESI-Tq-MS analysis revealed the presence of several flavonoids, among which we identified five possible flavonoids c-heterosides (luteolin-7-O-pyranosyl-3-O-glucoside, apigenin-6-8-di-C-glycoside, apigenin-6-C-arabinoside-8-C-glycoside, isoorientin, isovitexin). The diabetic rats (treated intraperitoneally with alloxan, 150 mg/kg) treated with Fr-BuOH (20 mg/kg/day for 90 days) presented improvement in blood glucose, serum levels of fructosamine, lipid profile and urea. Furthermore, the Fr-BuOH reduced both platelet aggregation and the production of oxidant species in diabetic animals. CONCLUSIONS: These results suggested that flavonoid C-glycosides present in the Fr-BuOH may be beneficial for the diabetic state, preventing complications induced by diabetes.


Subject(s)
Diabetes Complications/prevention & control , Diabetes Mellitus, Experimental/drug therapy , Flavonoids/therapeutic use , Glycosides/therapeutic use , Passiflora/chemistry , Phytotherapy , Plant Extracts/therapeutic use , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Apigenin/analysis , Apigenin/pharmacology , Apigenin/therapeutic use , Blood Glucose/metabolism , Chromatography, High Pressure Liquid , Diabetes Complications/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/complications , Flavones/analysis , Flavones/pharmacology , Flavones/therapeutic use , Flavonoids/analysis , Flavonoids/pharmacology , Fructosamine/blood , Glucosides/analysis , Glucosides/pharmacology , Glucosides/therapeutic use , Glycosides/analysis , Glycosides/pharmacology , Luteolin/analysis , Luteolin/pharmacology , Luteolin/therapeutic use , Male , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Platelet Aggregation/drug effects , Rats, Wistar , Tandem Mass Spectrometry
8.
Vet J ; 270: 105627, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33641803

ABSTRACT

This study aimed to characterize and correlate physiological and metabolic changes in horses fed a hypercaloric diet (HD). Nine mature horses with a mean initial body condition score of 2.9 ± 1 (scale, 1-9) were fed a high-calorie diet for 5 months. Fasting blood samples were collected before the study and biweekly for the duration of the project to determine the concentrations of cholesterol (CHOL), very low (VLDL), low (LDL) and high-density (HDL) lipoproteins, triglycerides, non-esterified fatty acids, and fructosamine. A low-dose oral glucose tolerance test (LGTT) was conducted before, 75 and 150 days after HD introduction. Mean arterial blood pressure was measured monthly. Following HD introduction, CHOL, LDL, HDL, and fructosamine blood concentrations increased (P < 0.001). These four variables were also positively and significantly correlated with the blood insulin response to LGTT. These findings confirm the occurrence of hypercholesterolemia concomitantly with insulin dysregulation development in horses exposed to HD.


Subject(s)
Biomarkers/blood , Diet/veterinary , Energy Intake , Horse Diseases/blood , Obesity/veterinary , Animals , Cholesterol/blood , Fructosamine/blood , Horse Diseases/etiology , Horses , Hypercholesterolemia/etiology , Hypercholesterolemia/veterinary , Insulin/blood , Lipids/blood , Metabolic Syndrome/blood , Metabolic Syndrome/etiology , Metabolic Syndrome/veterinary , Obesity/blood , Obesity/etiology
9.
Acta Diabetol ; 58(8): 975-981, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33743082

ABSTRACT

Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries. The strict control of glycemic oscillations is the principal therapeutic target, but this could be hard to achieve in uremic patients due to their unpredictable insulin sensitivity. Currently, the evaluation of the glycemic profile relies on serum markers (glycated hemoglobin HbA1c, glycated albumin, and fructosamine), capillary glucose blood control (self-monitoring of blood glucose), and interstitial glucose control (continue glucose monitoring). We conducted a systematic review of published articles on continue glucose monitoring in hemodialysis patients with type 2 diabetes, which included 12 major articles. Four studies found significant fluctuations in glucose levels during hemodialysis sessions. All studies reported a higher mean amplitude of glucose variations on the hemodialysis day. Three studies agreed that continue glucose monitoring is better than glycated hemoglobin in detecting these abnormalities. Moreover, continue glucose monitoring was more accurate and perceived as easier to use by patients and their caregivers. In patients with type 2 diabetes on hemodialysis, glucose levels show different variation patterns than the patients on hemodialysis without diabetes. Considering manageability, accuracy, and cost-effectiveness, continue glucose monitoring could be the ideal diagnostic tool for the patient with diabetes on hemodialysis.


Subject(s)
Blood Glucose Self-Monitoring/methods , Diabetes Mellitus, Type 2/blood , Diabetic Nephropathies/blood , Diabetic Nephropathies/therapy , Glycemic Control/methods , Renal Dialysis , Aged , Biomarkers/blood , Blood Glucose/analysis , Blood Glucose/metabolism , Female , Fructosamine/blood , Glycated Hemoglobin/analysis , Glycation End Products, Advanced , Humans , Kidney Failure, Chronic/blood , Male , Middle Aged , Serum Albumin , Glycated Serum Albumin
10.
J Diabetes Investig ; 12(4): 619-624, 2021 Apr.
Article in English | MEDLINE | ID: mdl-32767822

ABSTRACT

Obesity is increasing in patients with type 2 diabetes. A possible reduced association between fructosamine and glycated hemoglobin (HbA1c) in obese individuals has been previously discussed, but this has never been specifically evaluated in type 2 diabetes, and the potential influence of body fat mass and fat distribution has never been studied. We studied 112 type 2 diabetes patients with assessment of fat mass, liver fat and fat distribution. Patients with body mass index (BMI) above the median (34.9 kg/m2 ), versus BMI below the median, had a correlation coefficient between fructosamine and HbA1c significantly reduced (r = 0.358 vs r = 0.765). In the whole population, fructosamine was correlated negatively with BMI and fat mass. In multivariate analysis, fructosamine was associated with HbA1c (positively) and fat mass (negatively), but not with BMI, liver fat or fat distribution. The association between fructosamine and HbA1c is significantly reduced in the most obese type 2 diabetes patients, and this is mostly driven by increased fat mass.


Subject(s)
Abdominal Fat/diagnostic imaging , Diabetes Mellitus, Type 2/blood , Fructosamine/blood , Glycated Hemoglobin/metabolism , Obesity/blood , Aged , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Obesity/complications , Obesity/diagnostic imaging , Prospective Studies
11.
Medicine (Baltimore) ; 99(40): e22337, 2020 Oct 02.
Article in English | MEDLINE | ID: mdl-33019410

ABSTRACT

At present, glycated hemoglobin (HbA1c) and glycated albumin (GA) are used to evaluate glycemic control in diabetic patients, but they cannot reflect insulin deficiency and/or insulin resistance.We investigated the feasibility of using estimated average glucose to fasting plasma glucose ratio (eAG/fPG ratio) to estimate insulin resistance in young adult diabetes. A total of 387 patients with type 2 diabetes were included and were stratified into 2 groups based on median values of the glycemic index ratio: the GA/A1c ratio <2.09 (n = 91) and ≥2.09 (n = 296); the eAG/fPG ratio <1.69 (n = 155) and ≥1.69 (n = 232). HbA1c, GA, fructosamine, insulin, and C-peptide levels were measured. The ratio of GA to HbA1c was calculated, and the homeostasis model assessment of ß-cell function and insulin resistance were determined. The homeostasis model assessment of insulin resistance level was significantly associated with the eAG/fPG ratio, but not with the ratio of GA to HbA1c, GA, HbA1c, and fructosamine levels. The ratio of estimated average glucose to fasting plasma glucose level correlates with insulin resistance in young adult diabetes.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Fasting/metabolism , Insulin Resistance/physiology , Adolescent , Adult , C-Peptide/blood , Child , Female , Fructosamine/blood , Glycated Hemoglobin/analysis , Glycation End Products, Advanced , Glycemic Index , Humans , Insulin/blood , Male , Serum Albumin/analysis , Young Adult , Glycated Serum Albumin
12.
PLoS One ; 15(9): e0238877, 2020.
Article in English | MEDLINE | ID: mdl-32886731

ABSTRACT

BACKGROUND AND OBJECTIVE: A recent study identified progranulin as a candidate biomarker for frailty, based on gene expression databases. In the present study, we investigated associations between serum progranulin levels and frailty in a population-based sample of late middle-age and older adults. METHODS: We utilized a cohort study that included 358 African Americans (baseline ages 49-65). Frailty was assessed by three established methods: the interview-based FRAIL scale, the Cardiovascular Health Study (CHS) frailty scale that includes performance-based measurements, and the Frailty Index (FI) that is based on cumulative deficits. Serum levels of the following proteins and metabolites were measured: progranulin, cystatin C, fructosamine, soluble cytokine receptors (interleukin-2 and -6, tumor necrosis factor α-1 and -2), and C-reactive protein. Sarcopenia was assessed using the SARC-F index. Vital status was determined by matching through the National Death Index (NDI). RESULTS: Serum progranulin levels were associated with frailty for all indices (FRAIL, CHS, and FI) but not with sarcopenia. Inflammatory markers indicated by soluble cytokine receptors (sIL-2R, sIL-6R, sTNFR1, sTNFR2) were positively associated serum progranulin. Increased serum progranulin levels at baseline predicted poorer outcomes including future frailty as measured by the FRAIL scale and 15-year all-cause mortality independent of age, gender, and frailty. CONCLUSIONS: Our findings suggest that serum progranulin levels may be a candidate biomarker for physical frailty, independent of sarcopenia. Further studies are needed to validate this association and assess the utility of serum progranulin levels as a potential biomarker for prevalent frailty, for risk for developing incident frailty, and for mortality risk over and above the effect of baseline frailty.


Subject(s)
Biomarkers/blood , Frailty/metabolism , Progranulins/blood , C-Reactive Protein/analysis , Cohort Studies , Cystatin C/blood , Female , Fructosamine/blood , Humans , Male , Middle Aged , Receptors, Cytokine/blood
13.
Diabetes Care ; 43(10): 2607-2613, 2020 10.
Article in English | MEDLINE | ID: mdl-32801129

ABSTRACT

OBJECTIVE: In African-born Blacks living in America, we determined by BMI category 1) prevalence of abnormal glucose tolerance (Abnl-GT) and 2) diagnostic value and reproducibility of hemoglobin A1c (HbA1c), fructosamine, and glycated albumin (GA). RESEARCH DESIGN AND METHODS: Participants (n = 416; male, 66%; BMI 27.7 ± 4.5 kg/m2 [mean ± SD]) had an oral glucose tolerance test with HbA1c, GA, and fructosamine assayed. These glycemic markers were repeated 11 ± 7 days later. Abnl-GT diagnosis required 0 h ≥5.6 mmol/L (≥100 mg/dL) and/or 2 h ≥7.8 mmol/L (≥140 mg/dL). Thresholds for HbA1c, GA, and fructosamine were the values at the 75th percentile for the population (39 mmol/mol [5.7%], 14.2%, and 234 µmol/L, respectively). RESULTS: Abnl-GT prevalence in the nonobese was 34% versus 42% in the obese (P = 0.124). Reproducibility was excellent for HbA1c and GA (both κ ≥ 0.8), but moderate for fructosamine (κ = 0.6). Focusing on HbA1c and GA in the nonobese, we found as single tests the sensitivities of HbA1c and GA were 36% versus 37% (P = 0.529). Combining HbA1c and GA, sensitivity increased to 58% because GA identified 37% of Africans with Abnl-GT not detected by HbA1c (P value for both tests vs. HbA1c alone was <0.001). For the obese, sensitivities for HbA1c, GA, and the combined tests were 60%, 27%, and 67%, respectively. Combined test sensitivity did not differ from HbA1c alone (P = 0.25) because GA detected only 10% of obese Africans with Abnl-GT not detected by HbA1c. CONCLUSIONS: Adding GA to HbA1c improves detection of Abnl-GT in nonobese Africans.


Subject(s)
Black People/ethnology , Glucose Intolerance/diagnosis , Glucose Intolerance/ethnology , Glycated Hemoglobin/analysis , Serum Albumin/analysis , Adult , Africa/ethnology , Aged , Biomarkers/analysis , Biomarkers/blood , Blood Glucose/analysis , Female , Fructosamine/analysis , Fructosamine/blood , Glucose Intolerance/epidemiology , Glucose Tolerance Test/methods , Glucose Tolerance Test/standards , Glycation End Products, Advanced , Hemoglobin, Sickle/analysis , Humans , Male , Middle Aged , Obesity/blood , Obesity/complications , Obesity/diagnosis , Obesity/ethnology , Predictive Value of Tests , Quality Improvement , Reproducibility of Results , United States/epidemiology , Young Adult , Glycated Serum Albumin
14.
Diabetes Care ; 43(10): 2379-2387, 2020 10.
Article in English | MEDLINE | ID: mdl-32788282

ABSTRACT

OBJECTIVE: In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA1c. We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA1c, glycated albumin, and fructosamine) compared with continuous glucose monitoring (CGM)-derived measurement of glycemia across estimated glomerular filtration rate (eGFR) in type 2 diabetes. RESEARCH DESIGN AND METHODS: A prospective cohort study was conducted of 104 participants with type 2 diabetes, 80 with eGFR <60 mL/min/1.73 m2 (not treated with dialysis) and 24 frequency-matched control subjects with eGFR ≥60 mL/min/1.73 m2. Participants wore a blinded CGM for two 6-day periods separated by 2 weeks, with blood and urine collected at the end of each CGM period. HbA1c, glycated albumin, and fructosamine were measured by high-performance liquid chromatographic, enzymatic, and colorimetric nitroblue tetrazolium methods, respectively. RESULTS: Within-person biomarker values were strongly correlated between the two CGM periods (r = 0.92-0.95), although no marker fully captured the within-person variability of mean CGM glucose. All markers were similarly correlated with mean CGM glucose (r = 0.71-77). Compared with mean CGM glucose, glycated albumin and fructosamine were significantly biased by age, BMI, serum iron concentration, transferrin saturation, and albuminuria; HbA1c was underestimated in those with albuminuria. CONCLUSIONS: Glycated albumin and fructosamine were not less variable than HbA1c at a given mean CGM glucose level, with several additional sources of bias. These results support measuring HbA1c to monitor trends in glycemia among patients with eGFR <60 mL/min/1.73 m2. Direct measurements of glucose are necessary to capture short-term variability.


Subject(s)
Biomarkers/blood , Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Renal Insufficiency, Chronic/blood , Aged , Biomarkers/analysis , Blood Glucose Self-Monitoring/methods , Case-Control Studies , Cohort Studies , Diabetes Mellitus, Type 2/diagnosis , Female , Fructosamine/blood , Glomerular Filtration Rate , Glycated Hemoglobin/analysis , Glycated Hemoglobin/metabolism , Glycation End Products, Advanced , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/physiopathology , Serum Albumin/analysis , Serum Albumin/metabolism , Glycated Serum Albumin
15.
Oxid Med Cell Longev ; 2020: 1730492, 2020.
Article in English | MEDLINE | ID: mdl-32655759

ABSTRACT

This study is aimed at assessing the antihyperglycemic, antihyperlipidemic, and antioxidant effects of Citrus reticulata (C. reticulata) fruit peel hydroethanolic extract and two flavonoids, hesperidin and quercetin, in nicotinamide (NA)/streptozotocin- (STZ-) induced type 2 diabetic rats. In addition, GC-MS and HPLC-MS analyses of the extract were performed and the results indicated the presence of multiple flavonoids including hesperidin, quercetin, naringin, and polymethoxylated flavones (nobiletin and tangeretin). To achieve the aim of the study, diabetic rats with NA/STZ-induced T2DM were orally treated with C. reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin at a dose of 100 mg/kg b.w./day for four weeks. The treatments with C. reticulata fruit peel extract, hesperidin, and quercetin significantly ameliorated the impaired oral glucose tolerance; the elevated serum fructosamine level; the diminished serum insulin and C-peptide levels; the altered HOMA-IR, HOMA-IS, and HOMA-ß cell function; the decreased liver glycogen content; the increased liver glucose-6-phosphatase and glycogen phosphorylase activities; the deleteriously affected serum lipid profile; the elevated serum AST and ALT activities; and the raised serum creatinine and urea levels in the diabetic rats. The treatments also produced remarkable improvement in the antioxidant defense system manifested by a decrease in the elevated liver lipid peroxidation and an increase in the lowered glutathione content and GPx, GST, and SOD activities. Furthermore, the three treatments enhanced the mRNA expression of GLUT-4 and the insulin receptor ß-subunit, but only quercetin produced a significant increase in the expression of adiponectin in adipose tissue of diabetic rats. In conclusion, C. reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin have potent antidiabetic effects which may be mediated through their insulinotropic effects and insulin-sensitizing actions. In addition, the alleviation of the antioxidant defense system by the extract, hesperidin, and naringin may have an important action to enhance the antidiabetic actions and to improve liver and kidney functions in NA/STZ-induced diabetic rats.


Subject(s)
Antioxidants/metabolism , Citrus/chemistry , Diabetes Mellitus, Experimental/drug therapy , Hesperidin/therapeutic use , Hypoglycemic Agents/therapeutic use , Plant Extracts/therapeutic use , Quercetin/therapeutic use , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Animals , Blood Glucose/metabolism , C-Peptide/blood , Diabetes Mellitus, Experimental/chemically induced , Fructosamine/blood , Fruit/chemistry , Hypoglycemic Agents/chemistry , Insulin/blood , Insulin Resistance , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/pathology , Kidney/drug effects , Lipids/blood , Liver/drug effects , Liver/metabolism , Male , Niacinamide/adverse effects , Oxidative Stress/drug effects , Rats , Rats, Wistar , Streptozocin/adverse effects
16.
Pediatr Blood Cancer ; 67(9): e28499, 2020 09.
Article in English | MEDLINE | ID: mdl-32618413

ABSTRACT

In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c ) is unreliable and the American Diabetes Association recommends monitoring long-term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c . We present a case of a patient with SCD and cystic fibrosis-related diabetes on monthly chronic transfusions therapy (CTT) who had well-correlated "steady state" HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long-term glycemic control in patients with SCD on CTT programs.


Subject(s)
Anemia, Sickle Cell/blood , Biomarkers/blood , Blood Transfusion/methods , Cystic Fibrosis/blood , Diabetes Mellitus/blood , Fructosamine/blood , Glycated Hemoglobin/analysis , Adolescent , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/therapy , Blood Glucose/analysis , Cystic Fibrosis/complications , Cystic Fibrosis/therapy , Diabetes Mellitus/physiopathology , Diabetes Mellitus/therapy , Female , Humans , Prognosis
17.
Diabetes Res Clin Pract ; 165: 108233, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32497744

ABSTRACT

Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.


Subject(s)
Blood Glucose/analysis , Glucose Metabolism Disorders/diagnosis , Glycated Hemoglobin/analysis , Prediabetic State/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Blood Glucose Self-Monitoring , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Child , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Female , Fructosamine/blood , Glucose Intolerance/blood , Glucose Metabolism Disorders/blood , Glucose Tolerance Test , Glycation End Products, Advanced , Humans , Hyperglycemia/diagnosis , Longitudinal Studies , Male , Middle Aged , Prediabetic State/blood , Serum Albumin/analysis , Young Adult , Glycated Serum Albumin
18.
Vet Q ; 40(1): 132-139, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32315583

ABSTRACT

Background: In people, obesity and prediabetes mellitus might predispose to chronic kidney disease (CKD).Aims: To assess the association of overweight [Body condition score (BCS) >5] and glucose metabolism alterations, with established or potential markers of CKD. In addition, fructosamine and fasted blood glucose were compared as predictors of early abnormal glucose metabolism.Methods: 54 clinically healthy cats were included in a cross-sectional study comprising 25 neutered males and 29 (28 neutered) females aged 7.2 (5.5-9.4) years. Two potential markers of CKD, namely urinary free active transforming growth factor-ß1-creatinine ratio and urinary retinol binding protein-creatinine ratio were measured along with other parameters to assess CKD. A receiver operating curve was used to identify the best sensitivity and specificity of fructosamine to identify cats with fasting glucose >6.5 mmol/L.Results: No association was found between BCS and markers of CKD. Fructosamine was greater in cats with fasting glucose >6.5 mmol/L compared to those with fasting glucose ≤6.5 mmol/L. A fructosamine concentration ≥250 µmol/L was able to detect cats with hyperglycemia with a sensitivity of 77% and a specificity of 65%. Furthermore, fructosamine was more strongly correlated with fasting glucose than albumin-corrected fructosamine (r = 0.43, p = 0.002 vs r = 0.32, p = 0.026). Cats with higher fructosamine had lower serum symmetric dimethylarginine concentrations.Conclusion: The present study does not suggest an effect of obesity on renal function in domestic cats.Clinical relevance: Fructosamine might be of value for the diagnosis of prediabetes mellitus in cats.


Subject(s)
Cat Diseases/blood , Cat Diseases/etiology , Fructosamine/blood , Obesity/veterinary , Renal Insufficiency, Chronic/veterinary , Animals , Biomarkers/blood , Biomarkers/urine , Blood Glucose , Cat Diseases/urine , Cats , Creatinine/urine , Cross-Sectional Studies , Female , Kidney Function Tests , Male , Obesity/complications , Overweight , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Risk Factors , Spain
19.
EBioMedicine ; 55: 102759, 2020 May.
Article in English | MEDLINE | ID: mdl-32344198

ABSTRACT

BACKGROUND: The bile acid (BA) pathway plays a role in regulation of food intake and glucose metabolism, based mainly on findings in animal models. Our aim was to determine whether the BA pathway is altered and correctable in human obesity and diabetes. METHODS: We conducted 3 investigations: 1) BA receptor pathways were studied in NCI-H716 enteroendocrine cell (EEC) line, whole human colonic mucosal tissue and in human colonic EEC isolated by Fluorescence-activated Cell Sorting (ex vivo) from endoscopically-obtained biopsies colon mucosa; 2) We characterized the BA pathway in 307 participants by measuring during fasting and postprandial levels of FGF19, 7αC4 and serum BA; 3) In a placebo-controlled, double-blind, randomised, 28-day trial, we studied the effect of ileo-colonic delivery of conjugated BAs (IC-CBAS) on glucose metabolism, incretins, and lipids, in participants with obesity and diabetes. FINDINGS: Human colonic GLP-1-producing EECs express TGR5, and upon treatment with bile acids in vitro, human EEC differentially expressed GLP-1 at the protein and mRNA level. In Ussing Chamber, GLP-1 release was stimulated by Taurocholic acid in either the apical or basolateral compartment. FGF19 was decreased in obesity and diabetes compared to controls. When compared to placebo, IC-CBAS significantly decreased postprandial glucose, fructosamine, fasting insulin, fasting LDL, and postprandial FGF19 and increased postprandial GLP-1 and C-peptide. Increase in faecal BA was associated with weight loss and with decreased fructosamine. INTERPRETATIONS: In humans, BA signalling machinery is expressed in colonic EECs, deficient in obesity and diabetes, and when stimulated with IC-CBAS, improved glucose homeostasis. ClinicalTrials.gov number, NCT02871882, NCT02033876. FUNDING: Research support and drug was provided by Satiogen Pharmaceuticals (San Diego, CA). AA, MC, and NFL report grants (AA- C-Sig P30DK84567, K23 DK114460; MC- NIH R01 DK67071; NFL- R01 DK057993) from the NIH. JR was supported by an Early Career Grant from Society for Endocrinology.


Subject(s)
Bile Acids and Salts/administration & dosage , Blood Glucose/metabolism , Colon/drug effects , Diabetes Mellitus, Type 2/therapy , Ileum/drug effects , Obesity/therapy , Administration, Oral , Bile Acids and Salts/chemistry , Bile Acids and Salts/metabolism , Biological Transport , Capsules , Cell Line , Cholestenones/blood , Colon/metabolism , Colon/pathology , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Diffusion Chambers, Culture , Enteroendocrine Cells/cytology , Enteroendocrine Cells/drug effects , Enteroendocrine Cells/metabolism , Fasting/physiology , Fibroblast Growth Factors/blood , Fructosamine/blood , Gene Expression , Glucagon-Like Peptide 1/blood , Glucagon-Like Peptide 1/genetics , Homeostasis/drug effects , Homeostasis/physiology , Humans , Ileum/metabolism , Ileum/pathology , Insulin/blood , Obesity/genetics , Obesity/metabolism , Obesity/pathology , Postprandial Period , Primary Cell Culture , Receptors, G-Protein-Coupled/blood , Receptors, G-Protein-Coupled/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...